Skip to Main Content

Paper Details

Efficacy and safety of CPX-351 versus 7â¿¿+â¿¿3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial.
J Hematol Oncol
3
2022
Author NameAffiliation
Jorge CortesUniversity of Texas MD Anderson Cancer Center
Jorge CortesGeorgia Cancer Center, Augusta University
Tara L LinUniversity of Kansas Medical Center
  • 1 - 3

Datasets

Release 1.2